Study of Alofanib in Patients With Metastatic Gastric Cancer
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized multicenter phase 1b clinical trial of the safety and
pharmacokinetics, as well as the preliminary efficacy of monotherapy with alofanib, an
allosteric fibroblast growth factor receptor 2 inhibitor, in patients with advanced gastric
cancer who have exhausted the resource of standard therapy.